LSTA · NASDAQ
Lisata Therapeutics, Inc.
$1.08 0.00 (0.00%)
Company overview
Lisata Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing cellular therapies to reverse disease and promote the regeneration of damaged tissue. Its product candidates include HONEDRA, a recipient of SAKIGAKE designation that is in a Phase II clinical trial for the treatment of critical limb ischemia; XOWNA that is in a Phase IIb clinical trial for the treatment of coronary microvascular dysfunction; and CLBS201, a CD34+ cell therapy for the treatment of pre-dialysis patients with chronic kidney disease. The company was formerly known as NeoStem, Inc. and changed its name to Caladrius Biosciences, Inc. in June 2015. The company was formerly known as Caladrius Biosciences, Inc. and changed its name to Lisata Therapeutics, Inc. on September 15, 2022. Lisata Therapeutics, Inc.
- Sector
- Healthcare
- Industry
- Biotechnology
- Exchange
- NASDAQ
- Market cap
- $9.7M
- Employees
- 26
- Headquarters
- Basking Ridge, NJ
- Website
- lisata.com
- CEO
- David J. Mazzo
- Listed
- March 1, 1999
- P/E
- -0.58
- Dividend yield
- 0.03%
Company financials
- Revenue
- $170,000
- Gross profit
- $168,000
- Operating income
- -$17.3M
- EBITDA
- -$16.8M
- Net income
- -$16.4M
- EPS
- -$1.86
- Total assets
- $14.1M
- Total debt
- $0.00
- Gross margin
- 98.82%
- Net margin
- -9,618.24%
- Earnings yield
- -172.22%
No geographic segmentation.
Showing FY 2025
LSTA
1D
NASDAQ
O1.06H1.11L1.06C1.08-0.01 (-0.92%)Vol12.37K
News